Background
Since the 1980s, transrectal ultrasound (TRUS) guided systematic prostate biopsy is performed on patients with abnormal serum prostate-specific antigen (PSA) or suspicious digital rectal examination [
1]. This conventional method has been shown to have limited sensitivity for detecting prostate cancer (PCa), which of the false-negative rate may be as high as 47% [
2]. PSA related anxiety and repeated biopsy dilemma consist in many of the men with negative biopsies and persistently elevated serum PSA levels [
3]. Approximately 38% of them undergo a repeat biopsy within 5 years with cancer detection only in an additional 13 to 41% [
4].
In order to improve biopsy sensitivity, the concept of targeted biopsy (TB) on suspicious areas through magnetic resonance imaging (MRI) guidance was established [
5]. Although multiparametric MRI (mpMRI) offered an increased sensitivity and specificity on prostate biopsy guidance, the disadvantage of time-consuming and equipment-specialization made it not widely used [
6]. Recently, MRI-TRUS fusion technique has been developed and proposed, because of its combination of the soft tissue resolution of MRI and the practicability of TRUS [
7]. The mpMRI-TRUS image fusion biopsy system is a novel fusion technology which not only provides visualization of both recorded multiplanar reconstruction images on that one monitor, but also real-timely makes diagnostic or procedural decisions [
8]. Using one such fusion device, we got initial encouraging result for targeted prostate biopsy as reported by other researchers [
9‐
11]. Unfortunately, targeted MRI-TRUS fusion biopsy has not been well evaluated with free-hand transperineal approach, especially in Asian men with previously negative biopsy.
We present double center results to evaluate the impact of using mpMRI-TRUS image fusion technology for free-hand transperineal TB in Chinese men with prior negative biopsy and elevated PSA, and compare biopsy performance between TB and 12-core systematic biopsy (SB) in the cancer detection.
Results
Patient demographics and summary of fusion-guided biopsy findings are shown in Table
1. A total of 101 patients with prior negative biopsy and elevated PSA were suspected to have PCa with a PI-RADS score between 2 and 5 according to mpMRI examination. The mean age of the patient population was 68.9 years (SD 8.1) and mean number of MRI lesions was 1.9 (SD 1.0). The mean pre-fusion-guided biopsy PSA level was 10.8 ng/ml (SD 6.1) and prostate volume was 42.1 ml (SD 15.3). The mean number of targeted biopsy cores per patient was 4.2 (SD 1.5). Of 101 suspected patients, 41 (40.6%) were diagnosed PCa, including 16 (15.8%) insignificant and 25 (24.8%) significant cancers. Twenty-six patients who ultimately underwent prostatectomy were analyzed as a subgroup. Compared with all biopsy populaiton, patients who underwent prostatectomy were younger (65.2 vs 68.9 years,
P = 0.028), had smaller prostate volumes (35.1 vs 42.1 ml,
P = 0.015), had more MRI lesions (2.4 vs 1.9,
P = 0.029), and had more TB cores (4.9 vs 4.2,
P = 0.040).
Table 1
Patient demographics and summary of fusion-guided biopsy findings
Men, no. | 101 | 41 (40.6) | 26 (25.7) |
Age, year | 68.9 ± 8.1 | 67.8 ± 8.0 | 65.2 ± 7.2 |
PSA, ng/ml | 10.8 ± 6.1 | 11.3 ± 6.3 | 11.2 ± 6.3 |
Prostate volume, ml | 42.1 ± 15.3 | 39.4 ± 13.6 | 35.1 ± 11.8 |
Prior negative biopsy, no. | 1.5 ± 0.7 | 1.4 ± 0.6 | 1.4 ± 0.6 |
MRI lesions per patient, no. | 1.9 ± 1.0 | 2.1 ± 1.1 | 2.4 ± 1.0 |
PI-RAD score, no. (%) |
2 | 13 (12.9) | 1 (1.0) | 0 (0) |
3 | 31 (30.7) | 3 (3.0) | 0 (0) |
4 | 36 (35.6) | 19 (18.8) | 12 (11.9) |
5 | 21 (20.8) | 18 (17.8) | 14 (13.9) |
TB cores per patiens | 4.2 ± 1.5 | 4.8 ± 1.6 | 4.9 ± 1.8 |
Insignificant PCa | - | 16 (15.8) | 6 (5.9) |
Significant PCa | - | 25 (24.8) | 20 (19.8) |
Gleason score, no. (%) |
Gleason 6 | - | 17 (16.8) | 6 (5.9) |
Gleason 7 (3 + 4) | - | 9 (8.9) | 8 (7.9) |
Gleason 7 (4 + 3) | - | 7 (6.9) | 5 (5.0) |
Gleason ≥8 | - | 8 (7.9) | 7 (6.9) |
The comparative pathologic outcomes of prostate systemic biopsy and targeted biopsy are shown in Table
2 and Additional file
1: Table S1. Seventy-four patients (60 + 4 + 10) of the total population (73.3%) demonstrated exact agreement between TB and SB. TB diagnosed a similar PCa number (31 cases) to SB (27 cases). However, TB diagnosed 36% more significant cancers than SB (22 vs 13 cases,
P = 0.012). Among the 16 cases (4 + 10 + 2, 15.8%) in which TB revealed a higher risk category from SB group, 12 (10 + 2, 75%) were upgraded to significant cancers; whereas in 11 cases (8 + 2 + 1, 10.9%) which SB demonstrated a higher risk category from TB group, only 3 (2 + 1, 27.3%) were upgraded to significant cancers (
P = 0.022). In addition, the utility of TB alone lead to 10 less cases of cancer (24.4%), only 2 (20%) of these were significant. However, SB alone missed 14 cases of cancer (34.1%) and 10 (71.4%) were significant (
P = 0.036). In other words, when TB were combined with SB, an additional 14 cases of mostly significant PCa (10 cases) were diagnosed.
Table 2
Comparison of pathology from systematic biopsy and targeted biopsy for prostate cancer
TB |
No cancer. | 60 | 8 | 2 | 70 |
Insignificant cancer | 4 | 4 | 1 | 9 |
Significant cancer | 10 | 2 | 10 | 22 |
Totals | 74 | 14 | 13 | 101 |
The subgroup of 26 patients who underwent prostatectomy was also analyzed because pathology results from TB and SB could be compared against the whole-gland prostatectomy pathology (Table
3 and Additional file
1: Table S1). Within this subcohort, nine patients (the sum of all “no cancer” values for SB, 1 + 1 + 1 + 6) were diagnosed with PCa preoperatively only by TB, of whom 6 (66.7%) were significant cancer on whole-gland pathology. By contrast, 4 patients were diagnosed with PCa only by SB, only 1 (25%) were significant cancer on whole-gland pathology. When assessing the ability of preoperative biopsy to predict whole-gland pathology significance, the sensitivity of TB were 85% versus 45% for SB (
P = 0.019), while the specificities were same (83.3%). The total accuracy of TB were 84.6% versus 53.8% for SB (
P = 0.034).
Table 3
Comparison of whole-mount prostatectomy outcome with target biopsy and systematic biopsy pathology for prostate cancer
TB | SB | SB | |
No cancer | No cancer | 0 | No cancer | 0 | 4 |
Insig cancer | 2 | Insig cancer | 1 |
Sig cancer | 1 | Sig cancer | 0 |
Insig cancer | No cancer | 1 | No cancer | 1 | 4 |
Insig cancer | 1 | Insig cancer | 1 |
Sig cancer | 0 | Sig cancer | 0 |
Sig cancer | No cancer | 1 | No cancer | 6 | 18 |
Insig cancer | 0 | Insig cancer | 2 |
Sig cancer | 0 | Sig cancer | 9 |
Totals | 6 | 20 | 26 |
In order to identify any potential predictor associated with detection of PCa and significant cancer, univariate and multivariate analysis were performed (Table
4). PI-RADS score was significantly correlated with both the PCa and significant PCa (both
P < 0.001). Age, MRI lesions and PSA value of patients was only correlated with PCa (
P = 0.028,
P < 0.001 and
P = 0.03). The further multivariate analysis revealed that PSA value and PI-RADS score were independent predictive factors of the positive biopsy of PCa (
P = 0.004, OR = 1.22;
P = 0.001, OR = 3.64). Moreover, patients with high PI-RADS scores (4, 5) had an over 10-fold higher risk of positive biopsy compared to those with low PI-RADS scores (2, 3). Additional file
2: Figure S1 also showed a strong relationship between PI-RADS score and biopsy results.
Table 4
Univariate and multivariate analysis (logistic regression) predicting prostate cancer and clinically significant cancer
Age | 0.028 | 0.847 | 1.01 (0.93–1.10) | 0.812 |
PSA | <0.001 | 0.004 | 1.22 (1.07–1.39) | 0.070 |
Prostate volume | 0.114 | - | - | 0.397 |
Prior negative biopsy | 0.541 | - | - | 0.483 |
MRI lesions per patient | 0.030 | 0.193 | 1.67 (0.77–3.59) | 0.953 |
Biopsy cores | 0.165 | - | - | 0.587 |
PI-RAD score | <0.001 | 0.001 | 3.64 (1.74–7.63) | <0.001 |
4 + 5 vs 2 + 3 | <0.001 | <0.001 | 10.94 (3.0–40.1) | <0.001 |
Discussion
Imaging techniques, mainly mpMRI, have developed as an accurate modality in PCa detection. Lesions identified on mpMRI correlate with tumor location on radical prostatectomy specimens [
21]. Real-time fusion of mpMRI and TRUS images of the prostate is feasible and potentially able to identify cancerous regions for subsequent biopsy. This kind of biopsy can be performed using MRI localization information without requiring the cost, difficulties, or inconvenience of an MRI suite or MRI-compatible equipment. This double center prospective study evaluated the impact of real time free-hand transperineal targeted prostate biopsy guided by MRI-TRUS fusion imaging and made comparisons of biopsy performance between TB and traditional 12-core SB in Chinese men with prior negative biopsy sessions.
Our study indicated that PCa detection rate of TB and SB was 30.7 and 26.7% respectively, while the overall rate increased to 40.6% when combined the two approaches. With a mean of only 16.2 biopsies, we achieved a comparable overall detection rate to the others. Taira et al. reported a cancer yield ranging from 34.4 to 55.5% for men with 1, 2, and ≥3 prior negative biopsies [
2]. They used transperineal template guided mapping biopsy approach with an average of 54 cores. Walz et al. showed a cancer detection rate of 41% by using a 24-core transrectal saturation biopsy in men with at least two prior negative 8-core biopsies [
4]. It indicated that MRI-TRUS fusion guided free-hand transperineal biopsy with lower cores obtained higher or almost cancer detection rate compared to transperineal template mapping biopsy or transrectal saturation approach. Our result was similar to Brock’s, with a TB detection rate of 26.7% and overall rate of 40.6% by using transrectal MRI/real-time elastography fusion biopsy [
22]. Besides, our overall cancer detection rate seemed higher than Sonn’s result of 34% [
23], who used transrectal MRI-TRUS fusion biopsy in men with one or more previously negative biopsies and elevated PSA levels. We considered that the inconsistent result was because of the different biopsy pathway and patient demography, with older mean age and higher average PSA level in our cohort.
Current evidence demonstrates the improved sensitivity for detecting high grade or clinically significant PCa using MRI-TRUS fusion guided TB than with 12-core SB [
9,
10,
24]. In this study, TB significantly increased the detection of significant PCa while decreasing the detection of insignificant cancer compared with SB in a repeat biopsy setting. When using the whole-gland pathology significance as the “gold standard”, TB had a greater accuracy than SB for significant cancer on prostatectomy and a higher sensitivity of 85% versus 45%. Thus, our results demonstrated that TB could significantly change the distribution of clinical significance in repeated biopsy patients diagnosed with PCa toward diagnosis of more significant disease.
The European Society of Urogenital Radiology (ESUR) published the PI-RADS to standardize the MRI scoring system in 2012 [
14], which had been validated in primary and repeat biopsy cohorts [
7,
25]. Portalez, D et al. considered that ESUR scoring system provided a clinically relevant stratification of the risk of showing PCa in the challenging situation of repeat biopsies [
25]. Brock M et al. reported that the prediction of PCa and significant cancer was calculated with an AUC of 0.79 and 0.81 for PI-RADS score in lesion of repeat biopsies. Sonn GA et al. showed that image grade [
26] of suspicion on MRI was the most powerful predictor of significant cancer on multivariate analysis [
23]. In our cohort, using univariate and multivariate analysis, PI-RADS score was proven to be the strongest predictor of PCa or significant cancer as well (Table
4). Moreover, a strong relationship existed between PI-RADS score and biopsy results (Additional file
2: Figure S1). Patients with high PI-RADS scores (4, 5) had an over 10-fold higher risk of biopsy positivity compared to those with low PI-RADS scores (2, 3).
It is well known that the incidence of infectious complications following TRUS guided transrectal prostate biopsy is steadily increased. In a European randomized trial of 10,474 prostate needle biopsies, the febrile complication rate was as high as 4.2% [
27]. In the patients of repeated transrectal biopsies, there was a higher chance of acquiring sepsis with organisms resistant to standard antibiotics, such as multiresistant
Escherichia coli [
28]. Recently, there was an increased interest in the use of a transperineal approach for prostate biopsy [
28,
29]. Transperineal prostate biopsy has the advantage of avoiding penetration of rectal mucosa and thus minimizing inoculation of the prostate with bowel flora. Many published series of transperineal prostate biopsy reported their incidence of febrile complication with either zero or close to zero [
28‐
30]. In this series, we use the prostate biopsy methodology of free-hand transperineal approach with general anesthesia, and no peri-procedure complication including infectious and anaesthetic complications was noted.
Several limitations of the present study needed to be mentioned. The study population consisted of patients referred to Chinese men in Eastern China, which could have induced selection bias. Second, patients with no lesion on mpMRI were excluded from the study, which could influence cancer detection rate of SB. Third, the sample size was small, which might have an effect on the results of the study.